Methods of diagnosing inflammatory bowel disease through RNASET2
AssigneeCedars-Sinai Medical Center
InventorsRebecca Gonsky, Stephan R. Targan, Richard L. Deem, Philip Fleshner, Dermot P. Mcgovern, Janine Bilsborough
Life of this patent
Estimating the term…
Abstract
The present invention describes methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNASET2, TL1A and/or IFN-γ. The invention further provides a process for patient identification and/or stratification.
Claims20
A method of treating inflammatory bowel disease (IBD) in a subject,
- the method comprising administering a therapeutically effective amount of an anti-Tumor Necrosis Factor Ligand 1 (anti-TL1A) antibody to the subject,
- wherein the subject has been identified as having one or more RNase T2 (RNASET2) gene alleles selected from the group consisting of an “A” allele of rs1819333, a “T” allele of rs2149092, a “G” allele of rs9355610, a “T” allele of rs2149085, a “G” allele of rs1410295, and a “G” allele of rs9366093, and
- wherein methylation of the RNASET2 gene of the subject is increased as compared to a control subject who has not been diagnosed with IBD.
A method of identifying a subject having inflammatory bowel disease (IBD) who is likely to benefit from treatment with an anti-Tumor Necrosis Factor Ligand 1 (anti-TL1A) antibody, wherein the method comprises:
- a) assessing a biological sample from the subject to determine the presence or absence of one or more RNase T2 (RNASET2) gene alleles selected from the group consisting of an “A” allele of rs1819333, a “T” allele of rs2149092, a “G” allele of rs9355610, a “T” allele of rs2149085, a “G” allele of rs1410295, and a “G” allele of rs9366093;
- and
- b) assessing the biological sample from the subject to determine a level of methylation of RNASET2;
- wherein the presence of one or more of the alleles and/or increased methylation of RNASET2 indicates that the subject is likely to benefit from treatment with the anti-TL1A antibody.
A method of treating inflammatory bowel disease (IBD) in a subject,
- the method comprising administering a therapeutically effective amount of an anti-Tumor Necrosis Factor Ligand 1 (anti-TL1A) antibody to the subject,
- wherein the subject has been identified as having each of an “A” RNase T2 (RNASET2) gene allele of rs1819333, a “G” RNASET2 allele of rs9355610, and a “T” RNASET2 allele of rs2149085.
Dependencies are inferred from the claim text.